Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Company (TAK)
NYSE:TAK
Earnings Data
Report Date
May 13, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.03Last Year’s EPS
-0.23Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted significant strategic and operational positives: three high-impact Phase III successes with NDAs submitted or filings underway, strong cash generation (adjusted free cash flow JPY 625.9bn), growth across several launch products (growth & launch products +6.7% CER; ENTYVIO +7.4% CER; QDENGA +22.1%) and maintained core OP/core EPS guidance through disciplined cost management. Offsetting these positives are meaningful near-term top-line pressures from VYVANSE LOE (9M revenue −3.3%), slowing growth in some legacy products (TAKHZYRO +2.4% CER), policy and reimbursement headwinds (Medicare Part D effects, ENTYVIO selected for IRA), China albumin softness and increased near-term investment needs for launches. Overall, the strategic R&D wins and strong cash flow provide a favorable outlook, but material near-term revenue and pricing risks remain.Company Guidance
Late-stage R&D Success — Three Positive Phase III Readouts
Takeda reported positive Phase III results for oveporexton, rusfertide and zasocitinib in 2025, each meeting or exceeding expectations. Oveporexton: ~85% of patients reached normative Epworth Sleepiness Scale (ESS) with statistically significant improvements across 14 primary/secondary endpoints; NDA submitted. Rusfertide: durable hematocrit control <45% through 52 weeks with improved patient-reported outcomes; NDA submitted. Zasocitinib: rapid efficacy (PASI75 within 4 weeks), >50% PASI90 at week 16 and ~30% PASI100; regulatory filing preparations underway with expected launch in H1 CY2027.
Growth & Launch Products Driving Revenue
Growth and launch products represent over 50% of total revenue and grew 6.7% at constant exchange rate (CER) year-to-date, an improvement versus the ~5% growth seen in Q1 and Q2.
ENTYVIO Momentum and Access Gains
ENTYVIO grew 7.4% at CER year-to-date. ENTYVIO Pen achieved formulary coverage with all three large PBMs and commercial coverage >80%, supporting management's position to be on track for its full-year 6% growth projection.
Strong Adjusted Free Cash Flow and Upgraded FCF Outlook
Adjusted free cash flow for the period was JPY 625.9 billion, generated even after a USD 1.2 billion upfront payment to Innovent Biologics in December; management upgraded the adjusted free cash flow forecast for the full year.
Maintained Core Profitability Targets Despite Headwinds
Management revised revenue guidance (to a low single-digit decline at CER) due to stronger-than-anticipated VYVANSE generic erosion, but maintained full-year guidance for core operating profit (core OP) and core EPS through disciplined OpEx management and cost efficiencies.
Updated Financial Guidance and Forecast Upside
Full-year revenue forecast set at JPY 4.53 trillion; core OP forecast JPY 1.15 trillion; core EPS forecast JPY 486. Management also noted a net increase to forecasts from FX and momentum (revenue +JPY 30 billion; core OP +JPY 20 billion).
Strong Vaccine and Selected Product Growth
QDENGA vaccine growth accelerated to 22.1%, driven primarily by Brazil. Subcutaneous IG products grew double digits, and overall IG was up 4.3% year-to-date. FRUZAQLA continues to expand with global rollout.
Strategic Pipeline Expansion with Innovent Partnership
Takeda added two innovative oncology assets (TAK-928 and TAK-921) via partnership with Innovent, with encouraging early clinical signals and plans for global development; shared investment and staged go/no-go decisions (TAK-928 60/40 split with Innovent).
TAK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TAK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 29, 2026 | $16.69 | $17.17 | +2.88% |
Oct 30, 2025 | $13.77 | $13.23 | -3.92% |
Jul 29, 2025 | $14.31 | $14.32 | +0.07% |
May 08, 2025 | $15.06 | $14.27 | -5.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Takeda Pharmaceutical Company (TAK) report earnings?
Takeda Pharmaceutical Company (TAK) is schdueled to report earning on May 13, 2026, Before Open (Confirmed).
What is Takeda Pharmaceutical Company (TAK) earnings time?
Takeda Pharmaceutical Company (TAK) earnings time is at May 13, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TAK EPS forecast?
TAK EPS forecast for the fiscal quarter 2025 (Q4) is 0.03.